XPost: sci.misc
https://www.propublica.org/article/how-big-pharma-company-stalled- tuberculosis-vaccine-to-pursue-bigger-profits? utm_source=substack&utm_medium=email
Tuberculosis kills 1.6 million people per year, and for years
pharmaceutical giant GSK has had an experimental vaccine that, in
trials, prevented half of those infected from getting sick, the most
successful TB vaccine ever. That was funded by all sorts of government
and nonprofit money that uses a GSK-patented adjuvant, which was also
produced thanks to government investment. It has not been released,
because instead of investing money in developing vaccines that could
save millions of lives in the developing world, GSK instead put all
its resources into a shingles treatment for the rich American market
where the people who tend to get it — seniors — have government
insurance. That shingles vaccine, Shingrix, has made them $14 billion
since 2018. Even though GSK appears to have no interest in bringing
that TB shot to market, they still control the adjuvant, so they were
able to keep everyone else from developing a life- saving shot. At
this point, a vaccine trial funded by the Bill and Melinda Gates
Medical Research Institute isn’t expected to end before 2028.
--- SoupGate-Win32 v1.05
* Origin: fsxNet Usenet Gateway (21:1/5)